Literature DB >> 25077677

[Bullous pemphigoid: diagnosis and therapy].

Andrea Kneisel1, Michael Hertl.   

Abstract

Bullous pemphigoid is the most common autoimmune bullous skin disease which occurs more often at higher age. Clinically it presents with tense blisters and eczematous lesions combined with severe pruritus. The pemphigoid-like diseases include mucous membrane pemphigoid, pemphigoid gestationis and linear IgA disease. Diagnosis is based on immunofluorescence microscopy and confirmatory tests (ELISA, immunoblotting). Classical bullous pemphigoid presents with IgG autoantibodies against BP180 and BP230. Treatment includes topical and systemic corticosteroids and adjuvant immunosuppressants.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25077677     DOI: 10.1007/s10354-014-0294-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  32 in total

1.  Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.

Authors:  SilkeC Hofmann; Sybille Thoma-Uszynski; Thomas Hunziker; Philippe Bernard; Corinna Koebnick; Angelika Stauber; Gerold Schuler; Luca Borradori; Michael Hertl
Journal:  J Invest Dermatol       Date:  2002-11       Impact factor: 8.551

2.  Pemphigus.

Authors:  W F LEVER
Journal:  Medicine (Baltimore)       Date:  1953-02       Impact factor: 1.889

Review 3.  Autoimmune bullous skin diseases. Part 1: Clinical manifestations.

Authors:  Andrea Kneisel; Michael Hertl
Journal:  J Dtsch Dermatol Ges       Date:  2011-10       Impact factor: 5.584

4.  Prediction of survival for patients with bullous pemphigoid: a prospective study.

Authors:  Pascal Joly; Jacques Benichou; Catherine Lok; Marie France Hellot; Philippe Saiag; Emmanuelle Tancrede-Bohin; Bruno Sassolas; Bruno Labeille; Marie Sylvie Doutre; Isabelle Gorin; Christine Pauwels; Olivier Chosidow; Frédéric Caux; Eric Estève; Yves Dutronc; Michèle Sigal; Catherine Prost; Hervé Maillard; Jean Claude Guillaume; Jean Claude Roujeau
Journal:  Arch Dermatol       Date:  2005-06

5.  Mortality of bullous pemphigoid in Switzerland: a prospective study.

Authors:  B Cortés; G Marazza; L Naldi; C Combescure; L Borradori
Journal:  Br J Dermatol       Date:  2011-08       Impact factor: 9.302

Review 6.  The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.

Authors:  Lawrence S Chan; A Razzaque Ahmed; Grant J Anhalt; Wolfgang Bernauer; Kevin D Cooper; Mark J Elder; Jo-David Fine; C Stephen Foster; Reza Ghohestani; Takashi Hashimoto; Thanh Hoang-Xuan; Gudula Kirtschig; Neil J Korman; Susan Lightman; Francina Lozada-Nur; M Peter Marinkovich; Bartly J Mondino; Catherine Prost-Squarcioni; Roy S Rogers; Jane F Setterfield; Dennis P West; Fenella Wojnarowska; David T Woodley; Kim B Yancey; Detlef Zillikens; John J Zone
Journal:  Arch Dermatol       Date:  2002-03

7.  The association of bullous pemphigoid and malignant disease: a case control study.

Authors:  V A Venning; F Wojnarowska
Journal:  Br J Dermatol       Date:  1990-10       Impact factor: 9.302

8.  Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.

Authors:  Giovanni Di Zenzo; Sybille Thoma-Uszynski; Valentina Calabresi; Lionel Fontao; Silke C Hofmann; Jean-Philippe Lacour; Francesco Sera; Leena Bruckner-Tuderman; Giovanna Zambruno; Luca Borradori; Michael Hertl
Journal:  J Invest Dermatol       Date:  2011-06-23       Impact factor: 8.551

Review 9.  Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.

Authors:  Martin Pfütze; Andrea Niedermeier; Michael Hertl; Rüdiger Eming
Journal:  Eur J Dermatol       Date:  2007-02-27       Impact factor: 3.328

10.  Whole body application of a potent topical corticosteroid for bullous pemphigoid.

Authors:  J B Terra; W J B Potze; M F Jonkman
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-04-03       Impact factor: 6.166

View more
  2 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  [Pemphigoid diseases. Autoimmune diseases in the elderly].

Authors:  O N Horváth; J Jankásková; A Walker; M Sárdy
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.